

Edgar Filing: XENOMICS INC - Form 8-K

XENOMICS INC  
Form 8-K  
November 04, 2008

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

October 29, 2008

-----

XENOMICS, INC.  
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

FLORIDA  
(STATE OR OTHER JURISDICTION OF INCORPORATION)

333-103083  
(COMMISSION FILE NUMBER)

04-3721895  
(I.R.S. EMPLOYER IDENTIFICATION NO.)

One Deer Park Drive, Suite F  
Monmouth Junction, NJ 08852  
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

(732) 438-8290  
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

On October 29, 2008, Xenomics, Inc. entered into a License Agreement with Sequenom, Inc. ("Sequenom").

Under the License Agreement, we licensed to Sequenom exclusive, world-wide rights to our patents for the development of prenatal research and diagnostic

Edgar Filing: XENOMICS INC - Form 8-K

products based on our proprietary Transrenal DNA/RNA (Tr-DNA/RNA) technology. In addition, we issued to Sequenom warrants to purchase up to 438,596 shares of our common stock at the exercise price of \$0.75 per share. The warrants expire on October 29, 2013.

The License Agreement provides for up-front payments to us totaling \$1,000,000 between the effective date and January 2009 and royalties based on sales of licensed products, subject to certain minimum amounts. We retain the rights to all other applications of our Transrenal DNA technology, but granted Sequenom certain negotiation rights with respect to development and commercialization of products for cancer indications. In addition, the license does not cover our current test for fetal gender determination based solely on detection of Y chromosome, which we are preparing for possible commercialization in 2009. The License Agreement contains customary terms and conditions, including with respect to indemnification and limitations of liability.

A copy of the press release we issued in connection with this agreement is attached as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 Press release of Xenomics, Inc. dated October 30, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

XENOMICS, INC.

Date: November 3, 2008

By: /s/ Gary Anthony

-----  
Gary Anthony  
Vice President and Controller